Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892343 | 1.00 | PIK3CD (0.50) | PIK3CDDPP4DPP8DPP9LMNA | |
| SCHEMBL24729566 | 1.00 | PIK3CD (0.50) | PIK3CDDPP4DPP8DPP9LMNA | |
| SCHEMBL29302247 | 1.00 | PIK3CD (0.50) | PIK3CDDPP4DPP8DPP9LMNA | |
| SCHEMBL15429769 | 1.00 | PIK3CD (0.50) | PIK3CDDPP4DPP8DPP9LMNA | |
| SCHEMBL888602 | 1.00 | PIK3CD (0.50) | PIK3CDDPP4DPP8DPP9LMNA | |
| SCHEMBL21023383 | 0.79 | PIK3CD (0.44) | PIK3CD | |
| SCHEMBL26959605 | 0.78 | PIK3CD (0.39) | PIK3CDLMNACYP2C9 | |
| SCHEMBL26448946 | 0.78 | PIK3CD (0.39) | PIK3CDLMNACYP2C9 | |
| SCHEMBL23748937 | 0.78 | PIK3CD (0.39) | PIK3CDLMNACYP2C9 | |
| SCHEMBL29296256 | 0.75 | PIK3CD (0.37) | PIK3CDDPP4LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20170204110-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | PIK3CD 1683/4885DPP4 483/4885DPP8 250/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | PIK3CD 2048/4885DPP4 350/4885DPP8 249/4885 |
| US-20170204110-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | PIK3CD 2698/4885DPP4 3095/4885DPP8 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.